Evidence map›Paper›PMID 40500288›Full record

ArticleNPJ vaccines2025

Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2.

Jiin Felgner, Jenny E Hernandez-Davies, Erwin Strahsburger, Emily Silzel, Rie Nakajima, Aarti Jain, Jacob Laster, Jui-Lin Chiang, Yali Tsai, Philip L Felgner and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiin Felgner *Vaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Jenny E Hernandez-Davies *Vaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Erwin Strahsburger *Vaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Emily SilzelVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Rie NakajimaVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Aarti JainVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Jacob LasterVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Jui-Lin ChiangVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
Yali TsaiPolaris Pharmaceuticals, LLC, San Diego, CA, USA.
Philip L FelgnerVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA.
D Huw DaviesVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA. ddavies@uci.edu.
Li LiangVaccine Research and Development Center, Department of Physiology and Biophysics, University of California Irvine, Irvine, CA, USA. lliang3@uci.edu.

Funding

Defining molecular mechanisms of combination adjuvants: a systems immunology, transcriptomics and imaging approachU01AI160397 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAVIES, DAVID HUW · 2021 to 2024
$2.4M
NIAID NIH HHS U01 AI160397
6 · The paper itself

Abstract

mRNA vaccines represent a promising alternative to conventional vaccines, as demonstrated by the rapid deployment of mRNA vaccines during the recent COVID-19 pandemic. In this work, we have adapted and fine-tuned various reported mRNA lipid nanoparticle (LNP) synthesis and preparation procedures, evaluated a range of ionizable cationic lipids, and identified top-performing LNP formulations. The impact of uridine modification on mRNA's ability to trigger immune responses has also been explored. Our findings indicate that both unmodified mRNA and N1-methyl pseudouridine-modified mRNA successfully induced an antigen-specific antibody response in mice, while the methoxy uridine-modified mRNA did not. Based on these studies, we constructed a bivalent Fluvid mRNA vaccine, consisting of LNPs encapsulating uridine-unmodified mRNA encoding either a transmembrane domain-deleted hemagglutinin or the full-length native spike protein. This vaccine stimulated robust T cell and B cell immune responses and conferred 100% protective efficacy against challenge with either influenza or SARS-CoV-2 viruses in the mouse model, without compromising efficacy compared to administering each monovalent vaccine individually. Our data suggest that the multivalent mRNA vaccine can offer protection against different viruses by generating humoral and cellular responses against multiple antigens at the same time.

Identifiers

PMID40500288
PMCPMC12159160

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.